Format

Send to

Choose Destination
See comment in PubMed Commons below
Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.

Long-term treatment with golimumab for severe uveitis.

Author information

1
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele , Milan , Italy and.

Erratum in

Abstract

PURPOSE:

To evaluate the long-term efficacy of golimumab in patients with severe recalcitrant uveitis who had inadequate response to previous biologics.

METHODS:

Retrospective study (13 patients with JIA, 4 with HLA-B27-associated uveitis). Indication for treatment was active uveitis despite biologics. Golimumab dosing was 50 mg monthly/subcutaneously.

MAIN OUTCOME MEASURES:

uveitis activity, visual acuity improvement, reduction of systemic therapy (corticosteroids/immunosuppressants), adverse events.

RESULTS:

Of 17 patients (34 affected eyes), response to golimumab was seen in 14 patients; at last visit uveitis was inactive in 12 patients. Three patients were nonresponders. Mean follow-up time on golimumab was 21.9 months. Visual acuity remained stable in 26 eyes, improved in 7, and worsened in 1. Mean systemic prednisolone dose before and after golimumab was 12.5-3.5 mg/day. One patient developed pulmonary infection.

CONCLUSIONS:

Golimumab may be a promising new therapeutic option for severe uveitis patients who have not responded to other biologics.

PMID:
24143896
DOI:
10.3109/09273948.2013.844265
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center